What is itrm stock mission?
Known for developing differentiated anti-infectives aimed at combating the global challenge of multi-drug resistant pathogens, ITRM stock mission is to significantly improve the health and wellbeing of patients suffering from life-threatening diseases around the globe.
How often are itrm stock predictions updated?
"ITRM" stock predictions are updated every 5 minutes with latest exchange prices by smart technical market analysis. Q&A about "ITRM" projections. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Iterum Therapeutics Plc.
How much have itrm shares lost over the last 5 days?
On average, ITRM traded 13.67 million shares daily over the last 100 days, which was above its volume of 12.07 million shares traded on the day. Over the last five days, ITRM shares have lost -2.59 percent, while they have lost -43.78% over the last month.
How much did itrm raise in its IPO?
(ITRM) raised $80 million in an initial public offering on Friday, May 25th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.
Will ITRM stock go back up?
Stock Price Forecast The 1 analysts offering 12-month price forecasts for Iterum Therapeutics PLC have a median target of 1.00, with a high estimate of 1.00 and a low estimate of 1.00. The median estimate represents a +351.06% increase from the last price of 0.22.
Is ITRM a good buy right now?
Out of 2 analysts, 0 (0%) are recommending ITRM as a Strong Buy, 0 (0%) are recommending ITRM as a Buy, 2 (100%) are recommending ITRM as a Hold, 0 (0%) are recommending ITRM as a Sell, and 0 (0%) are recommending ITRM as a Strong Sell.
What does Iterum therapeutics do?
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing significantly differentiated anti-infectives aimed at combating the global crisis of multi-drug resistant (MDR) pathogens.
Will Iterum get FDA approval?
Iterum will give UTI antibiotic another go with new trial after meeting with FDA. The FDA denied it in July, but now Iterum Therapeutics has another shot at gaining approval for its antibiotic after meeting with the regulator last week.
What is the price target for ITRM?
Stock Price Target ITRMHigh$1.00Median$1.00Low$1.00Average$1.00Current Price$0.23
Is ITRM approved?
Shares of Iterum Therapeutics plc (ITRM) - Get Iterum Therapeutics plc Report dropped Monday after the company announced that it will not get approval for the current form of its new drug application for oral sulopenem.
Is Iterum Therapeutics a buy right now?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last year. There are currently 1 sell rating an...
Are investors shorting Iterum Therapeutics?
Iterum Therapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 2,720,000 shares, a drop of...
When is Iterum Therapeutics' next earnings date?
Iterum Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for I...
How were Iterum Therapeutics' earnings last quarter?
Iterum Therapeutics plc (NASDAQ:ITRM) posted its quarterly earnings data on Friday, May, 13th. The company reported ($0.02) EPS for the quarter, to...
What price target have analysts set for ITRM?
3 equities research analysts have issued 12 month price objectives for Iterum Therapeutics' shares. Their forecasts range from $0.69 to $0.70. On a...
Who are Iterum Therapeutics' key executives?
Iterum Therapeutics' management team includes the following people: Mr. Corey N. Fishman , Pres, CEO & Director (Age 57, Pay $939.26k) Ms. Judit...
Who are some of Iterum Therapeutics' key competitors?
Some companies that are related to Iterum Therapeutics include Matinas BioPharma (MTNB) , KemPharm (KMPH) , Impel Pharmaceuticals (IMPL) , Vacc...
What other stocks do shareholders of Iterum Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Iterum Therapeutics investors own include Aeglea BioTherap...
When did Iterum Therapeutics IPO?
(ITRM) raised $80 million in an IPO on Friday, May 25th 2018. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Leerink Pa...
Have things been going well at Iterum Therapeutics lately?
How ITRM will be rectifying the deficiencies?
Known for developing differentiated anti-infectives aimed at combating the global challenge of multi-drug resistant pathogens, ITRM stock mission is to significantly improve the health and wellbeing of patients suffering from life-threatening diseases around the globe.
Early Morning Vibes: 4 Trending Stocks To Watch Right Now
Despite being disappointed by this news, ITRM stock management remains confident in sulopenem’s ability to help address the growing problem of antibiotic resistance. As a result, ITRM set out to work with the FDA to identify and resolve the issues efficiently to encourage its continued advancement.
Latest Stocks Videos
On February 12, American stock markets closed in the green. The S&P 500 Index climbed 0.47% to 3935 points, the NASDAQ rose 0.50%, and the
Zacks
In The Money: Groundhog Day: Mega-Cap Tech Stocks Out From the Shadows? Feb 02, 2022
Does Iterum work with the FDA?
Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank.
Who is the Motley Fool?
Iterum now plans to work with the FDA to learn more about the deficiencies mentioned in the agency's letter. CEO Corey Fishman said that his company will "resolve the issues as expeditiously as possible in order to continue advancing this much needed antibiotic."
ITRM Target Price
Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.
Iterum Therapeutics Plc ( ITRM ) Stock Market info
ITRM price target in 14 days: 0.500 USD* upside and 0.346 USD* downside. (Highest and lowest possible predicted price in a 14 day period)
Verde Bio Holdings Stock Forecast, "VBHI" Share Price Prediction Charts
Recommendations: Buy or sell Iterum Therapeutics stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Iterum Therapeutics share forecasts, stock quote and buy / sell signals below.
